RhumbLine Advisers
CMMB

RhumbLine Advisers’s Chemomab Therapeutics CMMB Stock Holding History

RhumbLine Advisers’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.8K Buy
18,366
+510
+3% +$871 ﹤0.01% 3677
2025
Q4 		$29.5K Buy
17,856
+8,351
+88% +$22.2K ﹤0.01% 3719
2025
Q3 		$25K Sell
9,505
-464
-5% -$1.71K ﹤0.01% 3751
2025
Q2 		$46.2K Buy
9,969
+4,007
+67% +$19.8K ﹤0.01% 3677
2025
Q1 		$26K Buy
5,962
+10
+0.2% +$70 ﹤0.01% 3697
2024
Q4 		$43.1K Sell
5,952
-941
-14% -$5.94K ﹤0.01% 3682
2024
Q3 		$43.3K Buy
6,893
+1,924
+39% +$10.8K ﹤0.01% 3701
2024
Q2 		$18.3K Buy
4,969
+312
+7% +$1.08K ﹤0.01% 3885
2024
Q1 		$14.5K Hold
4,657
– – ﹤0.01% 3810
2023
Q4 		$9.5K Buy
4,657
+3,946
+555% +$10.4K ﹤0.01% 3870
2023
Q3 		$2.54K Sell
711
-40
-5% -$187 ﹤0.01% 4089
2023
Q2 		$3.94K Buy
+751
New +$4.74K ﹤0.01% 4123

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $147M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers's CMMB Position: Q1 2026 in Review

RhumbLine Advisers increased its Chemomab Therapeutics (CMMB) stake by 2.9% in Q1 2026, buying an estimated $871 and bringing the position to 18,366 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

RhumbLine Advisers first reported a position in CMMB in Q2 2023 and has held it in 12 quarters since. The position peaked at $46.2K in Q2 2025. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • RhumbLine Advisers held 18,366 shares of Chemomab Therapeutics worth $28.8K as of Q1 2026.
  • RhumbLine Advisers bought 510 Chemomab Therapeutics shares in Q1 2026, an estimated $871.
  • Chemomab Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3677 holding.
  • RhumbLine Advisers first reported a position in Chemomab Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Chemomab Therapeutics position peaked at $46.2K in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.